Turning Point Brands Announces Fourth Quarter and Full Year 2021 Results
Turning Point Brands (TPB) reported a 10% increase in FY 2021 net sales to $445.5 million and a 19.8% rise in adjusted EBITDA to $108.1 million. Q4 2021 sales remained steady at $105.3 million, despite a 22% decline in NewGen sales. The gross profit for Q4 fell 3.8% to $50.3 million, with net income down 20.3% to $11.5 million. Diluted EPS was $0.57, compared to $0.68 a year prior. Zig-Zag products showed significant growth, while Stoker’s experienced moderate growth. The company faces challenges in its NewGen segment due to regulations.
- FY 2021 net sales increased 10% to $445.5 million.
- Adjusted EBITDA rose 19.8% to $108.1 million for FY 2021.
- Zig-Zag Products net sales increased 32.9% to $176.5 million for FY 2021.
- Stoker's Products net sales increased 7.3% to $124.3 million for FY 2021.
- The company repurchased 477,707 shares at an average price of $38.09.
- Q4 2021 net income decreased 20.3% to $11.5 million.
- Q4 2021 gross profit decreased 3.8% to $50.3 million.
- NewGen Products segment sales declined 22% for Q4 and 7.5% for FY 2021 due to regulatory impacts.
-FY 2021 Net Sales Increased 10.0 Percent Year-Over-Year
-FY 2021 Adjusted EBITDA Increased 19.8 Percent Year-Over-Year
Q4 2021 vs. Q4 2020
-
Net sales were comparable with Q4 2020 at
despite a 22 percent decline in NewGen sales$105.3 million -
Gross profit decreased 3.8 percent to
$50.3 million -
Net income decreased 20.3 percent to
$11.5 million -
Adjusted EBITDA decreased 7.6 percent to
(see Schedule A for a reconciliation to net income)$23.8 million -
Diluted EPS of
and Adjusted Diluted EPS of$0.57 as compared to$0.66 and$0.68 in the same period one year ago, respectively (see Schedule B for a reconciliation to Diluted EPS)$0.77
FY 2021 vs FY 2020
-
Net sales increased 10.0 percent to
$445.5 million -
Gross profit increased 14.7 percent to
$217.8 million -
Net income increased 36.3 percent to
$52.1 million -
Adjusted EBITDA increased 19.8 percent to
(see Schedule A for a reconciliation to net income)$108.1 million -
Diluted EPS of
and Adjusted Diluted EPS of$2.52 as compared to$3.03 and$1.85 in the same period one year ago, respectively (see Schedule B for a reconciliation to Diluted EPS)$2.60
“Our fourth quarter results capped off another strong year of performance for
Zig-Zag Products Segment (44 percent of total net sales in the quarter)
For the fourth quarter, net sales of Zig-Zag Products increased 13.6 percent to
For the quarter, Zig-Zag Products segment gross profit increased 4.7 percent to
For the full year, net sales of Zig-Zag Products increased 32.9 percent to
For the full year, Zig-Zag Products segment gross profit increased 31.2 percent to
“Our Zig-Zag business experienced organic growth during the quarter despite a double-digit percentage growth headwind from the re-stocking of cigar wraps channel inventory in the prior year period,” said
Stoker’s Products Segment (30 percent of total net sales in the quarter)
For the fourth quarter, net sales of Stoker’s Products increased 8.3 percent to
For the quarter, the Stoker’s Products segment gross profit increased 10.4 percent to
For the full year, net sales of Stoker’s Products increased 7.3 percent to
For the full year, the Stoker’s Products segment gross profit increased 10.2 percent to
“Our Stoker’s Products segment delivered robust growth during the quarter,” continued Purdy. “MST continues to lead the way with double-digit growth from volume gains and increased pricing as we look to drive further distribution growth from here.”
NewGen Products Segment (26 percent of total net sales in the quarter)
For the fourth quarter, net sales of NewGen Products decreased 22.0 percent to
For the quarter, NewGen Products gross profit decreased 40.6 percent to
For the full year, net sales of NewGen Products decreased 7.5 percent to
For the full year, NewGen Products gross profit decreased 5.9 percent to
“NewGen continues to navigate multiple challenges driven by the evolving regulatory environment,” said Purdy. “We began building a last mile network infrastructure that had completed over 38,000 shipments prior to the PACT Act implementation in October. Since then, we have improved our operational positioning having received an exemption with the
Recent Events
CLIPPER® Lighters Distribution Agreement
As detailed in a separate press release, TPB today announced that it has entered into an agreement with Flamagas, a renowned lighter manufacturer, for exclusive distribution of CLIPPER® lighters in
Performance Measures in the Fourth Quarter
Fourth quarter consolidated selling, general and administrative (“SG&A”) expenses were
The fourth quarter SG&A included the following notable items:
-
of stock options, restricted stock and incentive expense as compared to$1.5 million in the year-ago period$0.6 million -
of transaction expenses as compared to$0.2 million in the year-ago period$1.2 million -
of FDA PMTA-related expenses compared to none in the year-ago period$0.7 million -
in outbound freight expense compared to$4.3 million in the year-ago period with the increase due to higher shipping costs on vapor products related to PACT Act implementation and higher freight costs across all segments$3.4 million -
from the accounting consolidation of Turning Point Brands Canada in the current quarterly period$1.7 million
Total gross debt as of
During the quarter, the Company spent
2022 Outlook
At this time, TPB projects the following for 2022:
-
Zig-Zag Products sales of
to$193 $203 million -
Stoker’s Products sales of
to$127 $134 million
Given the dynamic regulatory environment impacting the vape industry, it is difficult to provide reliable guidance for the NewGen Products segment. However, the Company’s current expectation is to generate consolidated adjusted EBITDA in-line with fiscal year 2021 despite anticipated volatility in the NewGen Products segment.
Earnings Conference Call
As previously disclosed, a conference call with the investment community to review TPB’s financial results has been scheduled for
Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted accounting principles in
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as "anticipate," "believe," "expect," "intend," "plan" and "will" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. As a result, these statements are not guarantees of future performance and actual events may differ materially from those expressed in or suggested by the forward-looking statements. Any forward-looking statement made by TPB in this press release, its reports filed with the
Financial Statements Follow:
Consolidated Statement of Income | ||||||||
(dollars in thousands except share data) | ||||||||
(unaudited) | ||||||||
Three Months Ended |
||||||||
|
||||||||
2021 |
2020 |
|||||||
Net sales | $ |
105,283 |
|
$ |
105,285 |
|
||
Cost of sales |
|
54,952 |
|
|
52,969 |
|
||
Gross profit |
|
50,331 |
|
|
52,316 |
|
||
Selling, general, and administrative expenses |
|
31,613 |
|
|
30,127 |
|
||
Operating income |
|
18,718 |
|
|
22,189 |
|
||
Interest expense, net |
|
5,094 |
|
|
3,344 |
|
||
Investment loss (income) |
|
6,965 |
|
|
(70 |
) |
||
Gain on extinguishment of debt |
|
(7,485 |
) |
|
- |
|
||
Net periodic benefit income, excluding service cost |
|
- |
|
|
(8 |
) |
||
Income before income taxes |
|
14,144 |
|
|
18,923 |
|
||
Income tax expense |
|
2,889 |
|
|
4,545 |
|
||
Consolidated net income |
|
11,255 |
|
|
14,378 |
|
||
Net loss attributable to non-controlling interest |
|
(199 |
) |
|
- |
|
||
Net income attributable to |
$ |
11,454 |
|
$ |
14,378 |
|
||
Basic income per common share: | ||||||||
Net income attributable to |
$ |
0.61 |
|
$ |
0.74 |
|
||
Diluted income per common share: | ||||||||
Net income attributable to |
$ |
0.57 |
|
$ |
0.68 |
|
||
Weighted average common shares outstanding: | ||||||||
Basic |
|
18,707,286 |
|
|
19,160,740 |
|
||
Diluted |
|
22,153,988 |
|
|
22,743,881 |
|
||
Supplemental disclosures of statement of income information: | ||||||||
Excise tax expense | $ |
6,212 |
|
$ |
7,114 |
|
||
FDA fees | $ |
166 |
|
$ |
154 |
|
Consolidated Statement of Income | ||||||||
(dollars in thousands except share data) | ||||||||
(unaudited) | ||||||||
For the year ended |
||||||||
|
||||||||
2021 |
2020 |
|||||||
Net sales | $ |
445,471 |
|
$ |
405,111 |
|
||
Cost of sales |
|
227,637 |
|
|
215,121 |
|
||
Gross profit |
|
217,834 |
|
|
189,990 |
|
||
Selling, general, and administrative expenses |
|
127,513 |
|
|
125,563 |
|
||
Operating income |
|
90,321 |
|
|
64,427 |
|
||
Interest expense, net |
|
20,500 |
|
|
13,487 |
|
||
Investment loss (income) |
|
6,673 |
|
|
(198 |
) |
||
Gain on extinguishment of debt, net |
|
(2,154 |
) |
|
- |
|
||
Net periodic benefit cost, excluding service cost |
|
- |
|
|
989 |
|
||
Income before income taxes |
|
65,302 |
|
|
50,149 |
|
||
Income tax expense |
|
14,040 |
|
|
11,957 |
|
||
Consolidated net income |
|
51,262 |
|
|
38,192 |
|
||
Net loss attributable to non-controlling interest |
|
(797 |
) |
|
- |
|
||
Net income attributable to |
$ |
52,059 |
|
$ |
38,192 |
|
||
Basic income per common share: | ||||||||
Net income attributable to |
$ |
2.75 |
|
$ |
1.97 |
|
||
Diluted income per common share: | ||||||||
Net income attributable to |
$ |
2.52 |
|
$ |
1.85 |
|
||
Weighted average common shares outstanding: | ||||||||
Basic |
|
18,917,570 |
|
|
19,398,474 |
|
||
Diluted |
|
22,381,994 |
|
|
22,937,441 |
|
||
Supplemental disclosures of statement of income information: | ||||||||
Excise tax expense | $ |
27,353 |
|
$ |
22,997 |
|
||
FDA fees | $ |
679 |
|
$ |
552 |
|
Consolidated Balance Sheet | ||||||||
(dollars in thousands except share data) | ||||||||
(unaudited) | ||||||||
|
||||||||
ASSETS | 2021 |
2020 |
||||||
Current assets: | ||||||||
Cash | $ |
128,320 |
|
$ |
41,765 |
|
||
Accounts receivable, net of allowances of |
|
6,496 |
|
|
9,331 |
|
||
Inventories |
|
87,607 |
|
|
85,856 |
|
||
Other current assets |
|
26,746 |
|
|
26,451 |
|
||
Total current assets |
|
249,169 |
|
|
163,403 |
|
||
Property, plant, and equipment, net |
|
18,650 |
|
|
15,524 |
|
||
Deferred income taxes |
|
1,363 |
|
|
610 |
|
||
Right of use assets |
|
15,053 |
|
|
17,918 |
|
||
Deferred financing costs, net |
|
388 |
|
|
641 |
|
||
|
162,333 |
|
|
159,621 |
|
|||
Other intangible assets, net |
|
87,485 |
|
|
79,422 |
|
||
Master Settlement Agreement (MSA) escrow deposits |
|
31,720 |
|
|
32,074 |
|
||
Other assets |
|
35,399 |
|
|
26,836 |
|
||
Total assets | $ |
601,560 |
|
$ |
496,049 |
|
||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ |
7,361 |
|
$ |
9,201 |
|
||
Accrued liabilities |
|
32,937 |
|
|
35,225 |
|
||
Current portion of long-term debt |
|
- |
|
|
12,000 |
|
||
Other current liabilities |
|
38 |
|
|
203 |
|
||
Total current liabilities |
|
40,336 |
|
|
56,629 |
|
||
Notes payable and long-term debt |
|
414,172 |
|
|
302,112 |
|
||
Lease liabilities |
|
13,336 |
|
|
16,117 |
|
||
Other long-term liabilities |
|
- |
|
|
3,704 |
|
||
Total liabilities |
|
467,844 |
|
|
378,562 |
|
||
Commitments and contingencies | ||||||||
Stockholders' equity: | ||||||||
Preferred stock, |
|
- |
|
|
- |
|
||
Common stock, voting, |
|
197 |
|
|
195 |
|
||
Common stock, nonvoting, |
|
- |
|
|
- |
|
||
Additional paid-in capital |
|
108,811 |
|
|
102,423 |
|
||
Cost of repurchased common stock | ||||||||
(1,295,408 shares at |
|
(48,869 |
) |
|
(10,191 |
) |
||
Accumulated other comprehensive loss |
|
(195 |
) |
|
(2,635 |
) |
||
Accumulated earnings |
|
71,460 |
|
|
23,645 |
|
||
Non-controlling interest |
|
2,312 |
|
|
4,050 |
|
||
Total stockholders' equity |
|
133,716 |
|
|
117,487 |
|
||
Total liabilities and stockholders' equity | $ |
601,560 |
|
$ |
496,049 |
|
Consolidated Statement of Cash Flows | ||||||||
(dollars in thousands) | ||||||||
(unaudited) | ||||||||
For the Year Ended |
||||||||
|
||||||||
2021 |
2020 |
|||||||
Cash flows from operating activities: | ||||||||
Consolidated net income | $ |
51,262 |
|
$ |
38,192 |
|
||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Gain on extinguishment of debt |
|
(2,154 |
) |
|
- |
|
||
Pension settlement and curtailment loss |
|
- |
|
|
1,188 |
|
||
(Gain) loss on disposal of property, plant, and equipment |
|
(54 |
) |
|
123 |
|
||
Impairment loss |
|
- |
|
|
149 |
|
||
Loss on investments |
|
7,100 |
|
|
- |
|
||
Depreciation expense |
|
3,105 |
|
|
3,237 |
|
||
Amortization of other intangible assets |
|
1,907 |
|
|
1,781 |
|
||
Amortization of deferred financing costs |
|
2,541 |
|
|
2,230 |
|
||
Deferred income taxes |
|
(1,485 |
) |
|
4,742 |
|
||
Stock compensation expense |
|
7,557 |
|
|
2,554 |
|
||
Noncash lease (income) expense |
|
(167 |
) |
|
370 |
|
||
Gain on MSA escrow deposits |
|
(255 |
) |
|
- |
|
||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable |
|
3,317 |
|
|
(2,112 |
) |
||
Inventories |
|
(9 |
) |
|
(8,004 |
) |
||
Other current assets |
|
(134 |
) |
|
(5,373 |
) |
||
Other assets |
|
996 |
|
|
2,076 |
|
||
Accounts payable |
|
(2,367 |
) |
|
(5,064 |
) |
||
Accrued postretirement liabilities |
|
- |
|
|
(54 |
) |
||
Accrued liabilities and other |
|
(2,943 |
) |
|
7,643 |
|
||
Net cash provided by operating activities |
|
68,217 |
|
|
43,678 |
|
||
Cash flows from investing activities: | ||||||||
Capital expenditures | $ |
(6,156 |
) |
$ |
(6,135 |
) |
||
Acquisitions, net of cash acquired |
|
(16,416 |
) |
|
(39,441 |
) |
||
Payments for investments |
|
(16,657 |
) |
|
(19,250 |
) |
||
Restricted cash, MSA escrow deposits |
|
(19,664 |
) |
|
- |
|
||
Proceeds on the sale of property, plant and equipment |
|
54 |
|
|
3 |
|
||
Net cash used in investing activities |
|
(58,839 |
) |
|
(64,823 |
) |
Consolidated Statement of Cash Flows (Cont.) | ||||||||
(dollars in thousands) | ||||||||
(unaudited) | ||||||||
For the Year Ended |
||||||||
|
||||||||
2021 |
2020 |
|||||||
Cash flows from financing activities: | ||||||||
Proceeds from Senior Notes | $ |
250,000 |
|
$ |
- |
|
||
Payments of 2018 first lien term loan |
|
(130,000 |
) |
|
(16,000 |
) |
||
Settlement of interest rate swaps |
|
(3,573 |
) |
|
- |
|
||
Payment of promissory note |
|
(9,625 |
) |
|
- |
|
||
Payment of IVG note |
|
- |
|
|
(4,240 |
) |
||
Proceeds from unsecured note |
|
- |
|
|
7,485 |
|
||
|
- |
|
|
(1,737 |
) |
|||
Payment of dividends |
|
(4,096 |
) |
|
(3,802 |
) |
||
Payments of financing costs |
|
(6,921 |
) |
|
(194 |
) |
||
Exercise of options |
|
2,071 |
|
|
862 |
|
||
Redemption of options |
|
(2,111 |
) |
|
(1,523 |
) |
||
Common stock repurchased |
|
(38,678 |
) |
|
(10,191 |
) |
||
Net cash provided by (used in) financing activities | $ |
57,067 |
|
$ |
(29,340 |
) |
||
Net increase (decrease) in cash | $ |
66,445 |
|
$ |
(50,485 |
) |
||
Effect of foreign currency translation on cash | $ |
191 |
|
$ |
- |
|
||
Cash, beginning of period: | ||||||||
Unrestricted | $ |
41,765 |
|
$ |
95,250 |
|
||
Restricted |
|
35,074 |
|
|
32,074 |
|
||
Total cash at beginning of period | $ |
76,839 |
|
$ |
127,324 |
|
||
Unrestricted | $ |
128,320 |
|
$ |
41,765 |
|
||
Restricted |
|
15,155 |
|
|
35,074 |
|
||
Total cash at end of period | $ |
143,475 |
|
$ |
76,839 |
|
Non-GAAP Financial Measures
To supplement our financial information presented in accordance with generally accepted accounting principles in
We define “EBITDA” as net income before interest expense, loss on extinguishment of debt, provision for income taxes, depreciation and amortization. We define “Adjusted EBITDA” as net income before interest expense, loss on extinguishment of debt, provision for income taxes, depreciation, amortization, other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted diluted EPS” as diluted earnings per share excluding items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Operating Income” as operating income excluding depreciation, amortization, other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance.
Non-
In accordance with
Schedule A | ||||||||
Reconciliation of GAAP Net Income to Adjusted EBITDA | ||||||||
(dollars in thousands) | ||||||||
(unaudited) | ||||||||
Three Months Ended |
||||||||
|
||||||||
2021 |
2020 |
|||||||
Net income attributable to |
$ |
11,454 |
|
$ |
14,378 |
|
||
Add: | ||||||||
Interest expense, net |
|
5,094 |
|
|
3,344 |
|
||
Gain on extinguishment of debt |
|
(7,485 |
) |
|
- |
|
||
Income tax expense |
|
2,889 |
|
|
4,545 |
|
||
Depreciation expense |
|
792 |
|
|
755 |
|
||
Amortization expense |
|
476 |
|
|
477 |
|
||
EBITDA | $ |
13,220 |
|
$ |
23,499 |
|
||
Components of Adjusted EBITDA | ||||||||
Other (a) |
|
- |
|
|
(9 |
) |
||
Stock options, restricted stock, and incentives expense (b) |
|
1,542 |
|
|
568 |
|
||
Transactional expenses (c) |
|
190 |
|
|
1,178 |
|
||
FDA PMTA (d) |
|
708 |
|
|
- |
|
||
Corporate and vapor restructuring (e) |
|
1,026 |
|
|
517 |
|
||
Non-cash asset impairment (f) |
|
7,100 |
|
|
- |
|
||
Adjusted EBITDA | $ |
23,786 |
|
$ |
25,753 |
|
||
(a) |
Represents non-cash pension expense (income) and foreign exchange hedging. | |
(b) |
Represents non-cash stock options, restricted stock, incentives expense and Solace performance stock units. | |
(c) |
Represents the fees incurred for transaction expenses. | |
(d) |
Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA"). | |
(e) |
Costs during the three month period ended |
|
(f) |
Represents impairment of investment in dosist. |
Schedule A | |||||||
Reconciliation of GAAP Net Income to Adjusted EBITDA | |||||||
(dollars in thousands) | |||||||
(unaudited) | |||||||
For the Year Ended |
|||||||
|
|||||||
2021 |
2020 |
||||||
Net income attributable to |
$ |
52,059 |
|
$ |
38,192 |
||
Add: | |||||||
Interest expense, net |
|
20,500 |
|
|
13,487 |
||
Gain on extinguishment of debt |
|
(2,154 |
) |
|
- |
||
Income tax expense |
|
14,040 |
|
|
11,957 |
||
Depreciation expense |
|
3,105 |
|
|
3,237 |
||
Amortization expense |
|
1,907 |
|
|
1,781 |
||
EBITDA | $ |
89,457 |
|
$ |
68,654 |
||
Components of Adjusted EBITDA | |||||||
Other (a) |
|
- |
|
|
988 |
||
Stock options, restricted stock, and incentives expense (b) |
|
7,557 |
|
|
2,555 |
||
Transactional expenses (c) |
|
1,267 |
|
|
3,087 |
||
FDA PMTA (d) |
|
1,668 |
|
|
14,435 |
||
Corporate and vapor restructuring (e) |
|
1,026 |
|
|
517 |
||
Non-cash asset impairment (f) |
|
7,100 |
|
|
- |
||
Adjusted EBITDA | $ |
108,075 |
|
$ |
90,236 |
||
(a) |
Represents non-cash pension expense (income) and foreign exchange hedging. | |
(b) |
Represents non-cash stock options, restricted stock, incentives expense and Solace performance stock units. | |
(c) |
Represents the fees incurred for transaction expenses. | |
(d) |
Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA"). | |
(e) |
Costs during the year ended |
|
(f) |
Represents impairment of investment in dosist. |
Schedule B | ||||||||
Reconciliation of GAAP diluted EPS to Adjusted diluted EPS | ||||||||
(dollars in thousands except share data) | ||||||||
(unaudited) | ||||||||
Three Months Ended | ||||||||
2021 |
2020 |
|||||||
GAAP diluted EPS | $ |
0.57 |
|
$ |
0.68 |
|
||
Other (a) |
|
- |
|
|
(0.00 |
) |
||
Gain on extinguishment of debt (b) |
|
(0.27 |
) |
|
- |
|
||
Stock options, restricted stock, and incentives expense (c) |
|
0.06 |
|
|
0.02 |
|
||
Transactional expenses (d) |
|
0.01 |
|
|
0.04 |
|
||
FDA PMTA (e) |
|
0.03 |
|
|
- |
|
||
Corporate and vapor restructuring (f) |
|
0.04 |
|
|
0.02 |
|
||
Non-cash asset impairment (g) |
|
0.26 |
|
|
- |
|
||
Impact of quarterly tax items to effective tax rate (h) |
|
(0.02 |
) |
|
0.01 |
|
||
Adjusted diluted EPS (i) | $ |
0.66 |
|
$ |
0.77 |
|
||
Total may not foot due to rounding |
(a) |
Represents non-cash pension expense (income) and foreign exchange hedging reporting tax effected at the quarterly tax rate. | ||||
(b) |
Represents gain on extinguishment of debt tax effected at the quarterly tax rate. | ||||
(c) |
Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs tax effected at the quarterly tax rate. | ||||
(d) |
Represents the fees incurred for transaction expenses tax effected at the quarterly tax rate. | ||||
(e) |
Represents costs associated with applications related to the FDA PMTA tax effected at the quarterly tax rate. | ||||
(f) |
Costs during the year ended |
||||
(g) |
Represents impairment of investment in dosist tax effected at the quarterly tax rate. | ||||
(h) |
Represents adjustment from quarterly tax rate to annual projected tax rate of |
||||
(i) |
Diluted shares outstanding includes the full 3.2 million share dilution of debt conversion without a 1.1 million share offsetting impact from capped call transactions. |
Schedule B | |||||||
Reconciliation of GAAP diluted EPS to Adjusted diluted EPS | |||||||
(dollars in thousands except share data) | |||||||
(unaudited) | |||||||
For the Year Ended | |||||||
2021 |
2020 |
||||||
GAAP diluted EPS | $ |
2.52 |
|
$ |
1.85 |
||
Other (a) |
|
- |
|
|
0.03 |
||
Gain on extinguishment of debt (b) |
|
(0.08 |
) |
|
- |
||
Stock options, restricted stock, and incentives expense (c) |
|
0.27 |
|
|
0.08 |
||
Transactional expenses (d) |
|
0.04 |
|
|
0.10 |
||
FDA PMTA (e) |
|
0.06 |
|
|
0.48 |
||
Corporate and vapor restructuring (f) |
|
0.04 |
|
|
0.02 |
||
Non-cash asset impairment (g) |
|
0.25 |
|
|
- |
||
Impact of quarterly tax items to effective tax rate (h) |
|
(0.06 |
) |
|
0.03 |
||
Adjusted diluted EPS (i) | $ |
3.03 |
|
$ |
2.60 |
||
Total may not foot due to rounding |
(a) |
Represents non-cash pension expense (income) and foreign exchange hedging reporting tax effected at the YTD tax rate. | ||||
(b) |
Represents gain on extinguishment of debt tax effected at the YTD tax rate. | ||||
(c) |
Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs tax effected at the YTD tax rate. | ||||
(d) |
Represents the fees incurred for transaction expenses tax effected at the YTD tax rate. | ||||
(e) |
Represents costs associated with applications related to the FDA PMTA tax effected at the YTD tax rate. | ||||
(f) |
Costs during the year ended |
||||
(g) |
Represents impairment of investment in dosist tax effected at the YTD rate. | ||||
(h) |
Represents adjustment from annual tax rate to annual projected tax rate of |
||||
(i) |
Diluted shares outstanding includes the full 3.2 million share dilution of debt conversion without a 1.1 million share offsetting impact from capped call transactions. |
Schedule C | |||||||||||||||||||||||||
Reconciliation of GAAP Gross Profit to Adjusted Gross Profit and GAAP Operating Income to Adjusted Operating Income | |||||||||||||||||||||||||
(dollars in thousands) | |||||||||||||||||||||||||
(unaudited) | |||||||||||||||||||||||||
Consolidated | Zig-Zag | Stoker's | NewGen | ||||||||||||||||||||||
4th Quarter | 4th Quarter | 4th Quarter | 4th Quarter | 4th Quarter | 4th Quarter | 4th Quarter | 4th Quarter | ||||||||||||||||||
2021 |
2020 |
2021 |
2020 |
2021 |
2020 |
2021 |
2020 |
||||||||||||||||||
Net sales | $ |
105,283 |
$ |
105,285 |
$ |
46,051 |
$ |
40,522 |
$ |
31,184 |
$ |
28,785 |
$ |
28,048 |
|
$ |
35,978 |
||||||||
Gross profit | $ |
50,331 |
$ |
52,316 |
$ |
26,397 |
$ |
25,212 |
$ |
16,942 |
$ |
15,340 |
$ |
6,992 |
|
$ |
11,764 |
||||||||
Adjustments: | |||||||||||||||||||||||||
Corporate and vapor restructuring |
|
264 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
264 |
|
|
- |
||||||||
Adjusted gross profit | $ |
50,595 |
$ |
52,316 |
$ |
26,397 |
$ |
25,212 |
$ |
16,942 |
$ |
15,340 |
$ |
7,256 |
|
$ |
11,764 |
||||||||
Operating income | $ |
18,718 |
$ |
22,189 |
$ |
19,212 |
$ |
20,461 |
$ |
12,687 |
$ |
11,746 |
$ |
(3,427 |
) |
$ |
1,308 |
||||||||
Adjustments: | |||||||||||||||||||||||||
Transaction costs |
|
190 |
|
1,178 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
|
- |
||||||||
FDA PMTA |
|
708 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|
|
- |
||||||||
Corporate and vapor restructuring |
|
1,026 |
|
517 |
|
- |
|
- |
|
- |
|
- |
|
1,026 |
|
|
- |
||||||||
Adjusted operating income | $ |
20,642 |
$ |
23,884 |
$ |
19,212 |
$ |
20,461 |
$ |
12,687 |
$ |
11,746 |
$ |
(2,401 |
) |
$ |
1,308 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220222005194/en/
Media Contacts
212.896.1204
rcona@kcsa.com
Investor Contacts
502.774.9238
ir@tpbi.com
Source:
FAQ
What were the FY 2021 financial results for Turning Point Brands (TPB)?
How did the net sales in Q4 2021 compare to Q4 2020 for TPB?
What is the diluted EPS for TPB in Q4 2021?
How did Zig-Zag Products perform in FY 2021 for TPB?